Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
124.83
+0.84 (0.68%)
Jan 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 122.63 - 125.50
52 week 35.98 - 147.63
Open 124.75
Vol / Avg. 883,830.00/865,995.00
Mkt cap 12.27B
P/E     -
Div/yield     -
EPS -5.25
Shares 98.33M
Beta 2.98
Inst. own 94%
Feb 6, 2018
Q4 2017 Alnylam Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 8, 2018
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference Q&A session
Jan 8, 2018
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference - Webcast
Jan 7, 2018
Alnylam Pharmaceuticals Inc to Discuss Sanofi Alliance Restructuring Corporate Call
Dec 14, 2017
Alnylam Pharmaceuticals Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference - Webcast
Nov 29, 2017
Alnylam Pharmaceuticals Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference - Webcast
Nov 29, 2017
Alnylam Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 8, 2017
Alnylam Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Webcast
Nov 7, 2017
Q3 2017 Alnylam Pharmaceuticals Inc Earnings Call - Webcast
Nov 7, 2017
Q3 2017 Alnylam Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -719.10% -869.63%
Operating margin -735.84% -900.33%
EBITD margin - -868.25%
Return on average assets -35.32% -30.96%
Return on average equity -45.20% -37.54%
Employees 514 -
CDP Score - -

Address

300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Officers and directors

Michael W. Bonney Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Barry E. Greene President
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Manmeet S. Soni Chief Financial Officer, Senior Vice President, Principal Financial Officer
Age: 39
Bio & Compensation  - Reuters
Yvonne L. Greenstreet M.D. Chief Operating Officer, Executive Vice President
Age: 54
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President - Research and Development
Age: 54
Bio & Compensation  - Reuters
Laurie B. Keating Senior Vice President, General Counsel, Secretary
Age: 62
Bio & Compensation  - Reuters
Pushkal Garg M.D. Senior Vice President - Clinical Development, Chief Medical Officer
Bio & Compensation  - Reuters
Theresa Heggie Senior Vice President, Head of Europe and Canada
Age: 57
Bio & Compensation  - Reuters
Peter F. Smith Ph.D. Senior Vice President - Early Development
Age: 59
Bio & Compensation  - Reuters